EpidStrategies, a Division of ToxStrategies LLC, is pleased to announce the addition of Dr. Michael Kelsh to our team, adding considerable depth to our qualifications in the fields of pharmacoepidemiology and occupational/environmental health. Dr. Kelsh brings to EpidStrategies 30+ years of experience in observational research and epidemiologic study design and implementation in the pharma, occupational and environmental health sectors. While working in the pharmaceutical/biotechnology industry, Dr Kelsh collaborated with clinical development, safety, and regulatory teams to provide real-world evidence (RWE) across the life cycle of medical therapeutics. Dr. Kelsh led efforts on the use of RWE for regulatory decision making by successfully developing a study that used historical controls to support a single-arm clinical trial, resulting in early FDA approval. His research has included studies of cancer, cardiovascular disease, respiratory and neurological disease, injury/musculoskeletal conditions, and epidemiologic studies of numerous occupational and environmental exposures. Much of this work has been published in 80+ peer-reviewed scientific articles.
Dr. Kelsh has a PhD in Epidemiology and MPH in Public Health, as well as an MA in Latin American Studies, from the University of California, Los Angeles. He has held Adjunct Professor positions at the UCSF Department of Epidemiology and Biostatistics, where he taught courses in pharmacoepidemiology, and at the UCLA School of Public Health, where he taught courses in occupational and environmental epidemiology.
The EpidStrategies Division of ToxStrategies focuses on epidemiological research and innovative solutions to address complex health benefits and conditions associated with pharmaceuticals, medical devices, and environmental chemicals.
For more information, contact Dr. Kelsh at EpidStrategies (mkelsh@epidstrategies.com; (805) 625-4529).